Apimeds Pharmaceuticals US, Inc (NYSE:APUS) IPO will take place February, 21 on the NYSE exchange under the ticker APUS.
The company is offering shares at an expected price between $4.00 and $5.00 per share with an insider lock-up period of 180 days ending on August 20, 2025.
See also: Benzinga IPO Calendar
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that is in the process of developing Apitox, a proprietary intradermally administered bee venom-based toxin, primary focus is to advance Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis ("OA") and, eventually, multiple sclerosis ("MS").
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.